CTOs on the Move

Golden Sap

www.goldensap.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.goldensap.com
  • 8 rang Saint-Jean-Baptiste RR 2
    Sainte-Aurí©lie, QC CAN G0M 1M0
  • Phone: 860.289.4053

Executives

Name Title Contact Details

Similar Companies

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia

Impax Laboratories

Impax Laboratories is a technology-based specialty pharmaceutical company utilizing our core competency in drug delivery and formulation expertise. We have a balanced business model consisting of a successful generic business targeting high-value solid oral and alternative dosage form Abbreviated New Drug Applications (ANDA), and a branded business currently focused on internally developing Central Nervous System (CNS) products where we can deliver meaningful patient benefits and develop strong intellectual property positions.

Transcend Orthotics & Prosthetics

Transcend orthotists and prosthetists are fully certified and experienced in serving the needs of our patients.

HatchMed

HatchMed - Bringing user centric design into the medical equipment world https://t.co/7vuyMSBnct #hospital #nurseproof #Seattle

Lundbeck

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company`s products are targeted at disease areas such as depression, schizophrenia, Parkinson`s disease and Alzheimer`s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck`s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centres in Denmark and China.